|
|
 |
 |
|
Through our Women's Cancer Programs, the Entertainment Industry Foundation is committed to saving lives by raising awareness about the importance of early detection of breast and reproductive cancers, providing funds to advance research on treatment and early detection methods, and supporting community programs that assist the millions of women at risk of or affected by cancer as well as their families.
EIF has a remarkable track record in raising awareness and funds in the fight against cancer. EIF's funding strategy is results-driven, bringing together some of the very best scientists and institutions in the country to collaborate on groundbreaking research projects to fast-track the development of better prevention methods and improved therapies for treatment of breast and reproductive cancers.
EIF's Women's Cancer Programs is comprised of several initiatives, each concentrating on a different aspect of the disease. Our National Women's Cancer Research Alliance focuses on new and more effective approaches to the treatment of women's cancers, while our Women's Cancer Research Fund is dedicated to developing better early detection tests, so these cancers can be caught in an early stage, when the cure-rate is much higher. Our latest endeavor, an ovarian cancer initiative, was created specifically to raise awareness for ovarian cancer, and funding for early detection and treatment research.
|
EIF's Women's Cancer Research Fund is one of three major initiatives within EIF's Women's Cancer Programs. Founded by a group of committed Hollywood leaders - chairs Kate Capshaw & Steven Spielberg and Rita Wilson & Tom Hanks, along with founders Kelly Chapman Meyer, Anne Douglas, Quinn Ezralow, Marion Laurie and Jamie Tisch - EIF's Women's Cancer Research Fund was established to support innovative research, education, and outreach directed at the development of more effective approaches to the early diagnosis, and prevention of all women's cancers.
Through this initiative, EIF assembled a "dream team" of nationally and internationally recognized scientists and clinicians, including four Nobel laureates, collaborating in a groundbreaking research project focused on a single objective: to discover biomarkers that can detect cancer at an early stage when survival rates are highest. The ultimate goal of EIF's Breast Cancer Biomarker Discovery Project is to develop a blood test for early discovery of breast cancer, and ultimately change the way physicians are able to forecast many types of cancers before they become life-threatening.
Honorary chairs Kate Capshaw and Rita Wilson along with The Women's Cancer Research Fund's founders Marion Laurie, Anne Douglas, Kelly Meyer, Quinn Ezralow, and Jamie Tisch.
|
|
Click here to learn more about EIF's Biomarker Discovery Project
Click here to learn more about the individual grantees
 EIF's National Women's Cancer Research Alliance is one of three major initiatives within EIF's Women's Cancer Programs. Through EIF's National Women's Cancer Research Alliance, co-founded with cancer activist Lilly Tartikoff, EIF funds some of the most promising research being conducted today to develop new and more effective approaches to the treatment of women's cancers. EIF grants have helped accelerate research that contributed to the development of a breakthrough gene treatment called Herceptin®, the first successful drug that seeks out a particular gene found in one of three cases of the most aggressive form of breast cancer.
After extensive trials, Dr. Dennis Slamon, director of the Revlon / UCLA Women's Cancer Research Program and chair of EIF's NWCRA Medical Advisory Board, announced that Herceptin® received FDA approval years ahead of schedule - ultimately saving the lives of countless women around the world. EIF grants have also supported other state-of-the-art therapies bringing new and innovative treatment approaches to breast cancer worldwide.
Click here to learn more about the individual grantees.
Ovarian cancer is the second leading gynecologic cancer and, the most deadly, accounting for more than 15,000 deaths annually. Because there is no accurate screening test to detect ovarian cancer, it is typically diagnosed at a late stage when it is more difficult to treat. To improve these outcomes, EIF's Women's Cancer Program's newest initiative focuses on ovarian cancer.
In order to fast-track breakthrough treatments and tests for ovarian cancer, EIF has selected four institutions for their groundbreaking work in ovarian cancer research and treatment, including: Cedars-Sinai Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute; The University of Texas M.D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Led by Dr. Beth Karlan, Director of the Cedars-Sinai Women's Cancer Research Institute, this women's cancer initiative represents a collaborative, multi-site undertaking designed to advance treatment of ovarian cancer through molecular profiling, biomarker discovery and targeted therapy development.
To learn more about what EIF is doing for ovarian cancer through the Callaway Golf Foundation's Women's Cancer Initiative, click here.
Click here to learn more about individual grantees.
|
|
 |
|
|
|
